CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03504488 |
Recruitment Status :
Recruiting
First Posted : April 20, 2018
Last Update Posted : January 31, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non Small Cell Lung Cancer Triple Negative Breast Cancer Melanoma Head and Neck Cancer | Biological: CAB-ROR2-ADC Biological: PD-1 inhibitor | Phase 1 Phase 2 |
This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active biologic (CAB) ROR2-targeted antibody drug conjugate (CAB-ROR2-ADC) BA3021 in patients with advanced solid tumors.
This study will consist of a dose escalation phase and a dose expansion phase with BA3021 in Phase 1. Phase 2 will study BA3021 alone or in combination with a PD-1 inhibitor.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 420 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2) |
Actual Study Start Date : | June 27, 2018 |
Estimated Primary Completion Date : | December 30, 2025 |
Estimated Study Completion Date : | December 30, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Monotherapy - CAB-ROR2-ADC (BA3021) alone
BA3021 alone Q2W dosing regimen
|
Biological: CAB-ROR2-ADC
Conditionally active biologic anti-ROR2 antibody drug conjugate
Other Name: BA3021 |
Experimental: Combination Therapy
CAB-ROR2-ADC (BA3021) with PD-1 inhibitor
|
Biological: CAB-ROR2-ADC
Conditionally active biologic anti-ROR2 antibody drug conjugate
Other Name: BA3021 Biological: PD-1 inhibitor PD-1 inhibitor |
- Phase 1: Safety Profile [ Time Frame: Up to 24 months ]Assess dose limiting toxicity as defined in the protocol
- Phase 1: Safety Profile [ Time Frame: Up to 24 months ]Assess maximum tolerated dose as defined in the protocol
- Phase 1 and 2: Safety Profile [ Time Frame: Up to 24 months ]Frequency and severity of AEs and/or SAEs
- Phase 2: Confirmed Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]Proportion of patients who achieve a confirmed CR or PR
- Phase 1: Pharmacokinetics [ Time Frame: Up to 24 months ]Plasma concentrations of ADC, total antibody and MMAE
- Phase 1: Pharmacokinetics [ Time Frame: Up to 24 months ]Peak Plasma Concentration (Cmax)
- Phase 1: Pharmacokinetics [ Time Frame: Up to 24 months ]Area under the plasma concentration versus time curve
- Phase 1: Confirmed Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]Proportion of patients who achieve a confirmed CR or PR
- Phase 1: Immunogenicity [ Time Frame: Up to 24 months ]The number and percentage of patients who develop detectable anti-drug antibodies (ADAs)
- Phase 1 and 2: Duration of response (DOR) [ Time Frame: Up to 24 months ]Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first
- Phase 1 and 2: Progression-free survival (PFS) [ Time Frame: Up to 24 months ]Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first
- Phase 1 and 2: Best overall response (OR) [ Time Frame: Up to 24 months ]All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy
- Phase 1 and 2: Disease control rate (DCR) [ Time Frame: Up to 24 months ]Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks
- Phase 1 and 2: Time to response (TTR) [ Time Frame: Up to 24 months ]Time from the first dose of investigational product until the first documentation of OR
- Phase 1 and 2: Overall survival (OS) [ Time Frame: Up to 24 months ]Time from the first dose of BA3021 treatment until death due to any cause
- Phase 1 and 2: Tumor size [ Time Frame: Up to 24 months ]Percent change from baseline in tumor size
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.
- Patients must have measurable disease.
- For the dose expansion phase: Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS)
- Age ≥ 18 years.
- Adequate renal function
- Adequate liver function
- Adequate hematological function
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least three months.
Exclusion Criteria:
- Patients must not have clinically significant cardiac disease.
- Patients must not have known non-controlled CNS metastasis.
- Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
- Patients must not have had major surgery within 4 weeks before first BA3021 administration.
- Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
- Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
- Patients must not be women who are pregnant or breast feeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03504488
Contact: BioAtla Medical Affairs | 8585580708 ext 3333 | medicalaffairs@bioatla.com |
Responsible Party: | BioAtla, Inc. |
ClinicalTrials.gov Identifier: | NCT03504488 |
Other Study ID Numbers: |
BA3021-001 |
First Posted: | April 20, 2018 Key Record Dates |
Last Update Posted: | January 31, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Melanoma Head and Neck Neoplasms Triple Negative Breast Neoplasms Neoplasms by Site Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue |
Nevi and Melanomas Skin Neoplasms Skin Diseases Breast Neoplasms Breast Diseases Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Antineoplastic Agents |